Advertising
Showing 1 to 15 of 163 entries
BUY
Their last quarter was very good, beating the street, but shares have been down. Part of their growth came from Covid testing, which grew well. Their medical devices business was up 8%, though the last two years halted elective surgeries. This hurt ABT but will improve (like JNJ did) because there's a huge backlog of surgeries. Earnings will grow for several years. He owns Stryker, but likes Abbott a lot.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
PAST TOP PICK
(A Top Pick May 31/22, Down 10.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with ABT has triggered its stop at $105. To remain disciplined we recommend covering the position at this time. This will result in a net investment loss of 12%, when combined with previous buy recommendations.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly ABT was embroiled in a whistleblower complaint that led to shutdown of a key baby formula plant. Now that the company has effectively been cleared of wrongdoing, the plant will be reopening and we again reiterate ABT as a TOP PICK. Recently reported earnings beat expectations and support at ROE of 28%. The have aggressively bought back shares and are retiring debt early. They are a Dividend Aristocrat, raising dividends for 50 consecutive years. We continue to recommend a stop loss at $105, looking to achieve $143 -- upside potential over 20%. Yield 1.6% (Analysts’ price target is $140.17)
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick May 18/21, Down 2%) A diversified healthcare company including diagnostics, nutrtiion, and generic drugs. They made many Covid testing kits, so they benefitted from the pandemic. Shares got hit as the pandemic waned. Still, they've made a lot of money, so they can use that cash flow to buy other companies. The medical devices business will ramp up as surgeries do. Last quarter, their infant formula controversy led them closing their plants; later, ABT was cleared of wrongdoing, so this business will ramp back up. They increase their dividend each year. Pays 2% yield now.
biotechnology / pharmaceutical
PAST TOP PICK
(A Top Pick Jun 08/21, Up 11%) Still likes. Now above his buy price of $110. Watch and wait for a pullback, as there will be volatility with diagnostics testing winding off.
biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In
TOP PICK
Stockchase Research Editor: Michael O'Reilly ABT has benefited from COVID-19 testing worldwide, is the second largest cardiologic technology company in the world, and is a large player in the continuous glucose monitoring market for diabetes. It trades at 30x earnings, compared to peers at 23x; however, forward earnings support a 23x valuation. It is a little expensive at over 5x book value. It pays a small dividend (that has been growing for 50 years consecutively), backed by a payout ratio under 50% of cash flow. Its most recent earnings beat expectations by 11% and support a strong 27% ROE. It has been building cash reserves while paying down debt. We would recommend setting a stop loss at $105, looking to achieve $143 -- 18% upside potential. Yield 1.59% (Analysts’ price target is $142.88)
biotechnology / pharmaceutical
TOP PICK

Has owned this for years, but is buying at current prices. They make the Covid-testing kits, totalling $10 billion revenues. Demand here will likely soften. The stock price is flat over the year, despite those revenues, but at least the cash flow from the testing can lead to more products and acquisition. They forecast they can grow revenues around 9%. Attractive stock price now. Diagnostic and medical devices are good business. Pharmas are selling to emerging markets. Their glucose monitoring system is doing well. Their heart products are a new source of growth. Attractive PE. (Analysts’ price target is $139.72)

biotechnology / pharmaceutical
VAGUE
An excellent company, a leader in medical diagnostics but he is not sure about current positioning. He doesn't want exposure to infectious diseases diagnostics. Wait for the area to act better and interest rates to stabilize.
biotechnology / pharmaceutical
BUY
Likes it. They got a lot of money from BinoxNOX, but they get no credit from it, so they need to deploy that money somehow. Meanwhile, their glucose monitor is selling very well--that's the reason to own it.
biotechnology / pharmaceutical
BUY
Has owned this many years. It's sensitive to the Covid testing environment, like now during Omicron. So, it's has a nice run from this increasing demand. But the market always looks forward, so Abbott doesn't enjoy that testing rise. They report later this month. She is waiting for a slightly lower entry point. Nobody knows what will happen with Covid, but the pandemic has given them a nice cash cushion while medical devices and diagonistics divisions are doing well and will grow, she think around 8-12%. She likes this long term.
biotechnology / pharmaceutical
COMMENT
An advisor could help the caller decide whether to hold or sell some. He doesn't own either The devices made by Abbott show promise for the stock so there is upside. The pharmaceutical side is not of particular interest. These are relatively defensive stocks but market could gravitate to cyclicals.
biotechnology / pharmaceutical
BUY
A Covid play, but he expects America to still be using their Covid testing kits for a long while to come despite medical breakthroughs.
biotechnology / pharmaceutical
BUY
They report Wednesday. They warned of an earnings shortfall. They created a fast Covid test--great news--but then Delta hit those test sales. He's long owned this. He likes their great medical devices.
biotechnology / pharmaceutical
TOP PICK
Diversified. Generics to EMs, medical devices, diagnostics, nutritionals. Covid tests. Outlook cut in June, as demand for rapid tests dropped. Now we're seeing increases in rapid tests. Good growth in med devices and diabetic monitoring. More in the pipeline. Attractive value. Increases dividend every year. She'd buy it here. Yield is 1.53%. (Analysts’ price target is $129.74)
biotechnology / pharmaceutical

Unlock the Weekly Buzzing Stocks

Become a member Or, Sign In
TOP PICK

There is renewed interest in the pharmaceutical sector after decades of being ignored. They are starting to act like value stocks. A good time to start a position in the pharma sector according to Norman Levine. Mentions have increased 22%.

biotechnology / pharmaceutical
Showing 1 to 15 of 163 entries

Abbott Labs(ABT-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 9

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 9

Stockchase rating for Abbott Labs is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abbott Labs(ABT-N) Frequently Asked Questions

What is Abbott Labs stock symbol?

Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N

Is Abbott Labs a buy or a sell?

In the last year, 9 stock analysts published opinions about ABT-N. 9 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.

Is Abbott Labs a good investment or a top pick?

Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.

Why is Abbott Labs stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abbott Labs worth watching?

9 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.

What is Abbott Labs stock price?

On 2022-07-01, Abbott Labs (ABT-N) stock closed at a price of $110.22.